News J&J lights up $1bn offer for pan-KRAS developer Firefly Johnson & Johnson has built its presence in KRAS drugs for cancer with a $1bn deal to buy Firefly Bio and its degrader-antibody conjugate platform.
News Roche doubles down on BTK with $2.3bn Nurix deal Roche is paying $700m upfront for rights to bexobrutideg, a BTK degrader that it says has potential across oncology, immunology, and neurology.
News ADC Therapeutics slumps on cancer drug safety scare Shares in ADC Therapeutics fell more than 50% after a non-Hodgkin lymphoma trial showed more deaths with its Zynlonta drug compared to a control.
News AbbVie's ovarian cancer drug Elahere gets NHS green light AbbVie's Elahere has become the first new NHS therapy in more than 20 years for resistant ovarian cancer, providing an alternative to chemotherapy.
News ASCO26: Celcuity punished as trial disappoints investors Celcuity is still confident it has a winner with its breast cancer treatment, gedatolisib, but investors seem less convinced by new VIKTORIA-1 data.
News ASCO26: In vivo CAR-Ts in the spotlight Data at ASCO on in vivo CAR-Ts from Kelonia and Legend add to the excitement about the emerging therapy class in both blood cancers and solid tumours.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.